Back to search
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
\*\*Translation:\*\* This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects…
The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologi…
The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed/refractory CD7-…
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lym…
To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-ce…